The European Commission has approved AstraZeneca’s drug Fasenra for the treatment of a condition called EGPA.

The fog lifts to reveal Parabilis, a newly rebranded cancer biotech company with support from well-known investors.

U.S. Border Protection is alerting pharmaceutical companies about the dangers of importing biological products incorrectly.

Novartis and Apellis are competing to get their treatments approved for a rare kidney disease. They have both released new data related to their drugs as part of this race.

Bavarian is looking to expand the use of the Mpox vaccine to include toddlers. They are starting a Phase II trial to test this.

Organon has acquired Dermavant, which means they have added more products to their skincare line.